47th week of 2011 patent applcation highlights part 36 |
Patent application number | Title | Published |
20110286933 | MONOFUNCTIONAL CARBOCYANINE DYES FOR IN VIVO AND IN VITRO IMAGING - The present invention provides symmetric carbocyanine dyes and dye precursors useful for fluorescence microscopy, and methods of making and using same. | 2011-11-24 |
20110286934 | MEMBRANE TRANSDUCTION PEPTIDES, POLYNUCLEOTIDES, AND METHODS - Isolated polypeptides, nucleic acids, and methods relating to cellular internalization of materials are described herein. Generally, the isolated polypeptides include a membrane transduction domain of human tissue factor pathway inhibitor-2 (TFPI-2). In some cases, the isolated polypeptide can be a fusion peptide that includes a membrane transduction domain of human TFPI-2 and a heterologous peptide domain. The nucleic acids include nucleic acids that encode the isolated polypeptides described herein. The methods generally include providing a composition that includes a membrane transduction domain of human TFPI-2 coupled to a material, and contacting the composition with a cell under conditions effective to permit the cell to internalize the composition. | 2011-11-24 |
20110286935 | Multi-Functional Nano-Device - A universal drug delivery platform for monoclonal antibody-based therapeutics is described. This universal platform resolves the problems of immunogenic response associated with the present monoclonal antibody based therapeutics by providing a multifunctional nano-device which comprises a well defined core/shell nano-structure that can function as a drug delivery platform linked to a monoclonal antibody through a single linking group. | 2011-11-24 |
20110286936 | TARGETING VECTOR-PHOSPHOLIPID CONJUGATES - Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA. | 2011-11-24 |
20110286937 | SYNTHETIC GLYCOLIPID-CONTAINING LIPOSOME - The present invention provides a glycolipid-containing liposome. In such a glycolipid-containing liposome, the glycolipid includes a plant ceramide portion and a sugar chain portion. The present invention also provides a method of producing a glycolipid-containing liposome. This method includes the following steps of: A) providing a glycolipid in which the glycolipid includes a plant ceramide portion and a sugar chain portion; and B) mixing the provided glycolipid with a liposome raw material and subjecting the mixture to conditions in which a liposome is formed. | 2011-11-24 |
20110286938 | NON-INVASIVE DETECTION OF COMPLEMENT-MEDIATED INFLAMMATION USING CR2-TARGETED NANOPARTICLES - Methods of non-invasive imaging of complement-mediated inflammation are provided. Compositions including CR-targeted ultrasmall superparamagnetic nanoparticles or aggregates thereof for use with those methods are also provided. | 2011-11-24 |
20110286939 | OSTEOGENIC COMPOSITIONS CONTAINING A COLORING AGENT - An osteogenic composition is provided for implantation at or near a target tissue site beneath the skin, the osteogenic composition comprising a growth factor and a coloring agent, wherein the coloring agent imparts color to the growth factor to allow the user to see the growth factor at or near the target tissue site. In some embodiments, a method is provided for accelerating bone repair, the method comprising mixing bone morphogenic protein- | 2011-11-24 |
20110286940 | COMPOSITION FOR THE TREATMENT OF KERATINOUS FIBERS COMPRISING AT LEAST ONE FIXING POLYMER AND AT LEAST ONE COMPOUND OF THE CERAMIDE TYPE AND METHODS FOR USING THE COMPOSITION - The invention relates to a cosmetic composition for the treatment of keratinous fibres, in particular human hair, comprising at least one anionic, nonionic, amphoteric or zwitterionic fixing polymer and at least one compound of the ceramide type as well as to the method of treatment using this composition. | 2011-11-24 |
20110286941 | COMBINATION OF TWO MATERIAL COMPOSITIONS FOR AN ORAL HYGIENE PRODUCT - The present application relates to a combination of two separately stored and jointly used compositions, which are suitable for the combat and the prevention of caries. Thereby, each of the two compositions respectively comprises a fluorine compound. Further, one composition comprises an acidic pH-value, while the other composition comprises a basic pH-value. | 2011-11-24 |
20110286942 | Topical Composition Comprising a Chaotrope - Topical compositions with a chaotrope are described. The compositions can comprise guanidinium chloride or a derivative thereof and an active, and they unexpectedly display rapid active delivery and improved active functionality upon application. | 2011-11-24 |
20110286943 | COMPOSITIONS AND METHODS FOR PROVIDING ULTRAVIOLET RADIATION PROTECTION - The present invention provides sunscreen compositions and associated methods. In one aspect, for example, a sunscreen composition can include a cosmetically acceptable carrier and a plurality of nanoparticles dispersed in the carrier with a dispersant. The nanoparticles include at least one sun-block functional group operable to provide UV radiation protection. In one aspect the nanoparticles can be nanodiamond particles. | 2011-11-24 |
20110286944 | METHODS AND COMPOSITIONS FOR SAFE AND EFFECTIVE TREATMENT OF ERYTHEMA - Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier. | 2011-11-24 |
20110286945 | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging - Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an α2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours. | 2011-11-24 |
20110286946 | SUNSCREEN COMPOSITIONS CONTAINING HYDROLYZED JOJOBA ESTERS FOR IMPROVED WATER RESISTANCE - Sunscreen compositions suitable for topical application are provided. The sunscreen composition includes at least one sunscreen active. Further, the sunscreen composition contains a water resistance agent including hydrolyzed jojoba esters, jojoba esters, and water. The water resistance agent provides for trapping the sunscreen active against the user's skin so that the sunscreen active is not removed by exposure to water. The sunscreen composition may further include potassium jojobate and/or jojoba alcohols. Also, the sunscreen composition may include glycerin for skin hydration purposes. | 2011-11-24 |
20110286947 | METHOD FOR MAKING UP OR CARING FOR KERATINOUS SUBSTANCES WITH NONCROSSLINKED POLYROTAXANES - A subject-matter of the invention is a cosmetic method for making up or for the nontherapeutic care of keratinous substances chosen from the nails, skin, lips or eyelashes, the method consisting in: a. depositing on the said keratinous substances at least one layer of at least one first composition comprising at least one first noncrosslinked polyrotaxane and at least one second noncrosslinked polyrotaxane, b. subjecting the said composition, simultaneously with or subsequent to its application, to at least one chemical, physicochemical and/or mechanical stimulus. | 2011-11-24 |
20110286948 | BACTERIAL CELLULOSE FILM AND USES THEREOF - A bacterial cellulose film is provided, including microbial fibers consisting of bacterial cellulose, wherein the microbial fibers are arranged in a density gradient in a direction of the bacterial cellulose film thickness. | 2011-11-24 |
20110286949 | STABLE COMPOSITIONS OF VARYING VISCOELASTICITY - The present invention is directed to cosmetic compositions having an unique texture and feel containing: (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) water; (d) optionally, at least one volatile solvent, other than water; (e) at least one non-volatile oil capable of solubilizing the oil-soluble polar modified polymer; and (f) optionally, at least one colorant. | 2011-11-24 |
20110286950 | COSMETIC COMPOSITIONS OF VARYING VISCOELASTICITY - The present invention is directed to stable cosmetic composition which is waterproof, comfortable and has a unique cushiony/bouncy texture and feel containing: (a) a reaction product of (i) at least one polyamine and (ii) at least one oil soluble high carbon polar modified polymer; (b) water; (c) at least one non-volatile solvent capable of solubilizing the polar modified polymer; and (d) optionally, at least one volatile solvent other than water,—and (e) optionally, at least one colorant. | 2011-11-24 |
20110286951 | TRANSFER RESISTANT COSMETIC COMPOSITIONS HAVING A UNIQUE TEXTURE AND FEEL CONTAINING AT LEAST TWO POLAR MODIFIED POLYMERS - The present invention also relates to a cosmetic composition comprising: (a) a reaction product of (i) at least one polyamine, (ii) at least one oil soluble polar modified polymer; and (iii) at least one oil soluble high carbon polar modified polymer; (b) water; (c) optionally at least one non-volatile solvent capable of solubilizing the polar modified polymers; (d) at least one volatile solvent, other than water; and (e) optionally, at least one colorant. | 2011-11-24 |
20110286952 | DERMOCOSMETIC COMPOSITION, AESTHETIC TREATMENT METHOD USING THE COMPOSITION, AND USE OF THE COMPOSITION FOR LIGHTENING THE PIGMENTATION OF THE SKIN - The invention relates to a dermocosmetic composition essentially characterized in that it comprises at least one hydrolase selected from acid phosphatases. | 2011-11-24 |
20110286953 | WHITENING AGENT, ANTI-AGING AGENT, AND ANTI-OXIDANT AGENT - [Problem] To provide a whitening agent having a superior skin whitening activity, and having a superior effect in lightening and whitening pigmentation, aging spots, freckles, chloasma, or the like after sunburn, and an antioxidant agent and an anti-aging agent having a superior free radical scavenging ability for preventing and controlling aging in the skin and skin diseases caused by active oxygen (free radicals), and having a high level of safety. | 2011-11-24 |
20110286954 | TRANSFER-RESISTANT EMULSION CONTAINING A SURFACTANT - The present invention is directed to a transfer resistant and long wear composition containing: (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) water; (d) at least one volatile solvent; (e) at least one non-volatile solvent capable of solubilizing the oil-soluble polar modified polymer; (e) at least one surfactant; and (f) at least one colorant. | 2011-11-24 |
20110286955 | EMULSION LIPSTICK COMPOSITION - The present invention is directed to a hydrating and moisturizing solid emulsion lipstick composition, capable of imparting enhanced shine and coverage, containing: (a) at least one polyamine; (b) at least one polar modified polymer; (c) water; (d) at least one non-volatile solvent; (e) at least one wax having a high melting point; and (e) optionally, at least one colorant. | 2011-11-24 |
20110286956 | NOVEL MULTI-ARM POLYETHYLENE GLYCOL, PREPARATION METHOD AND USES THEREOF - A novel multi-arm polyethylene glycol (PEG) (I) and preparation method thereof. Active derivatives (II) based on the multi-arm PEG. Gels formed of the active derivatives. Drug conjugates formed of the active derivatives and drug molecules and uses thereof in medical preparation. The multi-arm PEG is formed by polymerizing ethylene oxide with pentaerythritol oligomers as initiator, wherein PEG is the same or different and is a —(CH2CH2O)m-, the average value of m is an integer of 3-1000, l is an integer more than or equal to 2. An 8-arm PEG is preferred, wherein l is equal to 3. The active derivatives (II) comprise link groups X attached to PEG and active end groups F attached to X. | 2011-11-24 |
20110286957 | MULTIBLOCK COPOLYMERS - Provided herein are multiblock copolymers, as well as micelles and therapeutic compositions thereof. | 2011-11-24 |
20110286958 | HPMA POLYMER PLATINUM CHELATES - Polymeric platinum amidomalonate complexes, where the platinum is in +2 or +4 oxidation state, and where the complexes optionally contain tumor seeking groups, are useful in the treatment of cancer. | 2011-11-24 |
20110286959 | Copolymers for suppression of autoimmune diseases, and methods of use - Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. Fifty-mers of FEAK were effective inhibitors of MBP 85-99- or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones. These copolymers efficiently suppressed the mouse disease EAE, which was induced in a susceptible SJL/J (H-2 | 2011-11-24 |
20110286960 | CANCER THERAPY BY DOCETAXEL AND GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) - Neutropenia is the dose-limiting toxicity of the tri-weekly docetaxel (Taxotere®) schedule. Here, we evaluate in Metastatic Breast Cancer (MBC) patients (N=38) a computerized method for predicting docetaxel-induced neutropenia, and use the model to identify improved docetaxel and Granulocyte Colony Stimulating Factor (G-CSF) regimens. Pharmacokinetics/pharmacodynamics (PK/PD) models were created and simulated concomitantly with a mathematical granulopoiesis model. Individual baseline neutrophil counts and docetaxel schedules served as inputs. Our trial validated the model accuracy in predicting nadir timings (r=0.99), grade 3/4 neutropenia (86% success) and neutrophil profiles (r=0.62). Model was robust to CYP3A-induced variability, except for slightly less accurate grade 3/4 neutropenia predictions. Simulations confirm smaller toxicity of the weekly docetaxel regimen than the tri-weekly one, and suggest an optimal G-CSF support for alleviating neutropenia, 60 μg/day QD×3, 6-7 days post-docetaxel, administered tri- and bi-weekly, and 4 days post weekly docetaxel>33 mg/m | 2011-11-24 |
20110286961 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2011-11-24 |
20110286962 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS - Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. | 2011-11-24 |
20110286963 | HUMAN SOLUBLE CD146, PREPARATION AND USES THEREOF - The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD 146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD 146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells. | 2011-11-24 |
20110286964 | AZO-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS - The present invention provides compounds of Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R | 2011-11-24 |
20110286965 | ETHENYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS - The present invention provides compounds of Formula (A): (Chemical formula should be inserted here as it appears on abstract in paper form) (A) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein wherein each of R, R | 2011-11-24 |
20110286966 | Inhibitor of Endogenous Human Interferon-gamma - Modified endogenous human interferon-gamma (hIFN-γ), biologically inactive but preserving binding affinity to the hIFN-γ receptor, has applicability in the treatment of autoimmune diseases, especially multiple sclerosis. | 2011-11-24 |
20110286967 | LONG-ACTING INTERFERONS AND DERIVATIVES THEREOF AND METHODS THEREOF - A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed. | 2011-11-24 |
20110286968 | CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY - A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided. | 2011-11-24 |
20110286969 | DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS - The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as wet! as methods of using them to treat disorders associated with the HCV protease An illustrative inventsve compound is shown below: Formula (I). | 2011-11-24 |
20110286970 | METHOD FOR TREATING PARKINSON'S DISEASE - The present invention relates to the use of a filamentous bacteriophage, which displays an antibody that specifically binds to a pro-inflammatory cytokine, either alone or in combination with a filamentous bacteriophage that does not display a mammalian cell internalization signal, to treat Parkinson's disease. | 2011-11-24 |
20110286971 | TARGETED DRUG-CARRYING BACTERIOPHAGES - The present invention relates to the field of drug delivery. More specifically, the invention relates to the preparation and use of a bacteriophage conjugated through a labile/non labile linker or directly to at least 1,000 therapeutic drug molecules such that the drug molecules are conjugated to the outer surface of the bacteriophage. The bacteriophage optionally displays on its coat a ligand that endows it with specificity towards target cells. Thus, there is provided a targeted, high-capacity drug delivery system useful for the treatment of various pathological conditions. | 2011-11-24 |
20110286972 | VIRUS GROWING IN HYPOXIC CELL OR VIRUS VECTOR EXPRESSING GENE THEREIN - The present invention provides a virus or a viral vector capable of expressing a gene specifically in a cell having replication ability in a hypoxic state such as a cancer stem cell and injuring the cell, and pharmaceutical composition comprising the same. Specifically, the present invention provides a virus or a viral vector which comprises a gene encoding a fusion protein of an ODD and a protein essentially required for viral proliferation, and a pharmaceutical composition comprising the same. | 2011-11-24 |
20110286973 | METHODS FOR INTRODUCING HETEROLOGOUS CELLS INTO FISH - The invention provides methods of introducing heterologous cells into fish. After introduction cells remain viable, and in some instances proliferate, for sufficient time to conduct a variety of analyses on the heterologous cells or the fish or both. Such methods are useful for screening potential drugs for toxicity toward introduced cells or for capacity to stimulate differentiation and/or proliferation of introduced cells. Such methods are also useful for diagnosing the presence of small quantities of cancerous cells or pathogens in patient tissue samples. Such methods are also useful for culturing cells for subsequent use in cell or tissue engineering. | 2011-11-24 |
20110286974 | Method for treating diabetes and other glucose regulation disorders using stem cells - Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. | 2011-11-24 |
20110286975 | SYSTEMS AND METHODS FOR MAGNETIC GUIDANCE AND PATTERNING OF MATERIALS - Systems and methods generally useful in medicine, cellular biology, nanotechnology, and cell culturing are discussed. In particular, at least in some embodiments, systems and methods for magnetic guidance and patterning of cells and materials are discussed. Some specific applications of these systems and methods may include levitated culturing of cells away from a surface, making and manipulating patterns of levitated cells, and patterning culturing of cells on a surface. Specifically, a method of culturing cells is presented. The method may comprise providing a plurality of cells, providing a magnetic field, and levitating at least some of the plurality of cells in the magnetic field, wherein the plurality of cells comprise magnetic nanoparticles. The method may also comprise maintaining the levitation for a time sufficient to permit cell growth to form an assembly. | 2011-11-24 |
20110286976 | BI-SPECIFIC FUSION PROTEINS - Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network. | 2011-11-24 |
20110286977 | G6PC2-Encoded Beta Cell Surface Tags - The invention relates to G6PC2-encoded beta cell surface markers, methods of identifying and obtaining a culture cells comprising fully differentiated beta cells. Also contemplated is a method of sorting such cells, isolated cells and compositions thereof. | 2011-11-24 |
20110286978 | Genetically Intact Induced Pluripotent Cells Or Transdifferentiated Cells And Methods For The Production Thereof - The present disclosure relates to methods for dedifferentiating and transdifferentiating recipient cells, preferably human somatic cells. These methods minimize the risk of undesired genome sequence alteration. These methods employ reprogramming factors, which may be used alone or in certain combinations with one another. These methods have application especially in the context of cell-based therapies, establishment of cell lines, and the production of genetically modified cells. | 2011-11-24 |
20110286979 | CHEMOSENSITIZATION BY BI-FUNCTIONAL SMALL HAIRPIN RNA (bi-shRNA) - Compositions and methods of augmenting the anti-tumor activities of docetaxel and other taxanes by combination with a bi-functional small hairpin RNA (bi-shRNA) is described herein. The instant invention describes the interactive outcome of STMN1 knockdown with docetaxel. In vitro docetaxel (DOC) dose response assessments with or without co-treatment with bi-shRNA | 2011-11-24 |
20110286980 | METHODS FOR INDUCING SELECTIVE APOPTOSIS - Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient. | 2011-11-24 |
20110286981 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 2011-11-24 |
20110286982 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 2011-11-24 |
20110286983 | LONG LASTING DRUG FORMULATIONS - The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin. | 2011-11-24 |
20110286984 | GENE ENCODING HUMAN GLUCOKINASE MUTANT, ENZYME ENCODED BY THE SAME, RECOMBINANT VECTORS AND HOSTS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF, METHODS FOR TREATING AND PREVENTING DISEASES - Gene encoding human glucokinase mutant is provided. The gene has the nucleotide sequence chosen from the nucleotide sequence listed as SEQ ID NO:2 and the nucleotide sequence wherein the ORF region encodes the same amino acid sequence as the one encoded by ORF region (position 487 to 1884) of SEQ ID NO:2 and the rest of the region is same as the non-ORF region of SEQ ID NO:2. Human glucokinase mutant encoded by the gene, the recombinant vectors carrying the gene, the hosts comprising the vectors, pharmaceutical compositions thereof, uses thereof, and methods for treating and preventing diseases by using the same are provided. The human glucokinase mutant encoded by the gene has higher activity than that of the wild type human glucokinase, and thus provides a new way of controlling blood glucose and/or preventing and/or treating disturbance of carbohydrate metabolism, especially preventing and treating diabetes. | 2011-11-24 |
20110286985 | METHOD OF TREATMENT USING ORGANOTYPICALLY CULTURED SKIN TISSUE COMPRISING NIKS CELLS THAT EXPRESS EXOGENOUS HIF-1A - The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1, HIF-1α, or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue. | 2011-11-24 |
20110286986 | LACTOFERRIN AND ANGIOGENIN COMPOSITIONS AND USES THEREOF - Compositions are described which contain lactoferrin and angiogenin. The described compositions are useful in treatment of a variety of conditions, particularly in promoting bone health and relief of menopausal symptoms. | 2011-11-24 |
20110286987 | QUENCHING METHODS FOR RED BLOOD CELL PATHOGEN INACTIVATION - The present invention provides improved methods for treating red blood cell compositions with a pathogen-inactivating compound under conditions which provide suitable pathogen inactivation while maintaining cell vitality. Also provided methods of reducing dehydration in red blood cells, as well as treated red blood cell compositions. | 2011-11-24 |
20110286988 | FVIII Muteins for Treatment of Von Willebrand Disease - This invention relates to treatment of von Willebrand Disease by administration of Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties in subjects lacking von Willebrand Factor. | 2011-11-24 |
20110286989 | ANGIOGENIN COMPLEXES (ANGex) WITH LIPID-BASED SUBSTRATES AND USES THEREOF - Stabilized angiogenin compositions and methods of preparing stabilized angiogenin compositions by immobilization on a lipid-based substrate, such as a phospholipid or Coenzyme-Q10, are disclosed. | 2011-11-24 |
20110286990 | METHODS OF DIAGNOSING AND TREATING FIBROSIS - The present invention is directed to methods of diagnosing and treating a fibrotic condition in a mammalian subject. These methods involve measuring the levels of trimethylation at lysine residue 27 of histone-3 and/or measuring the expression levels of EZH2 or YY-1. Agents useful for treating fibrosis or a fibrotic condition are also disclosed. | 2011-11-24 |
20110286991 | PEPTIDES DERIVED FROM HMG-COA REDUCTASE AND COSMETIC AND/OR PHARMACEUTICAL COMPOSITION CONTAINING SAME - The present invention relates to peptides derived from human HMG-CoA reductase of general formula (I): | 2011-11-24 |
20110286992 | PERSONAL CARE COMPOSITION CONTAINING LEGHEMOGLOBIN - A personal care composition comprising leghemoglobin and at least one preservative selected from the group consisting of alcohols, glycols, parabens, hydantoins, quaternary nitrogen-containing compounds, isothiazolinones, aldehyde-releasing agents, and halogenated compounds. Preferably, the leghemoglobin is a nitrogen fixation root nodule extract providing a leghemoglobin concentration in the composition of between 0.0001% and about 10% based upon the total weight of the composition. Also disclosed is a method for preparing the personal care composition. | 2011-11-24 |
20110286993 | USE OF HSP70 AS A REGULATOR OF ENZYMATIC ACTIVITY - The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP. | 2011-11-24 |
20110286994 | METHODS AND COMPOSITIONS FOR IMPROVING GROWTH OF MEAT-TYPE POULTRY - The present invention provides methods of improving growth performance, improving the efficiency of feed utilization, increasing feed digestibility, and decreasing mortality of immature and developing animals receiving animal feed. Methods of producing a crude keratinase enzyme extract and animal feed supplements for achieving the same are also provided. | 2011-11-24 |
20110286995 | Drug Therapy for Celiac Sprue - Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | 2011-11-24 |
20110286996 | ANTIBIOTICS GE 81112 FACTORS A, B, B1, PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS, AND USE THEREOF - The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of | 2011-11-24 |
20110286997 | Genetic Alterations on Chromosome 16 and Methods of Use Thereof for the Diagnosis and Treatment of Type 1 Diabetes - Compositions and methods for the detection and treatment of T1D are provided. | 2011-11-24 |
20110286998 | METHODS FOR TREATING AND PREVENTING CANCERS THAT EXPRESS THE HYPOTHALAMIC-PITUITARY-GONADAL AXIS OF HORMONES AND RECEPTORS - Methods are provided for treating HPG axis-positive cancers, preventing or slowing proliferation of cells of HPG axis-positive cancer origin, preventing HPG axis-positive cancers in a patient at risk of contracting such cancers, preventing or inhibiting an upregulation of the cell cycle in HPG axis-positive cancer-derived cells in a patient, and decreasing the level of HPG axis-positive cancer-specific markers in a patient. | 2011-11-24 |
20110286999 | METHODS FOR REVERSING MULTIPLE RESISTANCE IN ANIMAL CELLS - The present invention is related to the use of a virus, preferably an adenovirus for reversing resistance in cells. | 2011-11-24 |
20110287000 | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASE - The present invention provides novel methods of treatment of multiple sclerosis and other autoimmune diseases or inflammatory disorders, and antagonists, including isolated binding proteins for use in the novel methods. There is provided a method of treating multiple sclerosis comprising the neutralization of the biological activity of IL-7 by binding to CD127 or IL-7. The isolated binding proteins may also neutralize the biological activity of TSLP. | 2011-11-24 |
20110287001 | METHOD OF TREATMENT - The invention provides methods for inducing apoptosis, comprising treatment of a patient with a TNFα inhibitor as well as with an IAP inhibitor and a TRAIL receptor agonist. The methods ameliorate the risk of unwanted effects, thereby resulting in an improved therapeutic index for IAP inhibitors in combination with a TRAIL receptor agonist. | 2011-11-24 |
20110287002 | ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF - Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed. | 2011-11-24 |
20110287003 | TREATMENT METHODS - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer. | 2011-11-24 |
20110287004 | MG53 COMPOSITIONS AND METHODS OF USE - Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins. | 2011-11-24 |
20110287005 | MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN AND USES THEREOF - The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders. | 2011-11-24 |
20110287006 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and an anti-Bcl-2 active agent. | 2011-11-24 |
20110287007 | Treatment and Prevention of Chronic Asthma Using Antagonists of Integrin AlphavBeta6 - The present invention relates to methods of asthma treatment and prevention using α | 2011-11-24 |
20110287008 | INHIBITION OF EMMPRIN TO TREAT MULTIPLE SCLEROSIS - The present invention provides new methods for the prevention of migration of leukocytes into the CNS. These methods, which rely on inhibition of EMMPRIN activity or expression, can be used to treat or slow the onset of diseases such as multiple sclerosis and EAE. | 2011-11-24 |
20110287009 | Production of Heteromultimeric Proteins - Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies. | 2011-11-24 |
20110287010 | Diagnostic methods and markers - The present invention relates to methods of detecting, monitoring and treating prostate cancer (PRC) OR prostatic intraepithelial neoplasia (PIN) or a predisposition to same. Provided for use in the methods is a novel cancer marker, PSPU43, as well as bioassays and kits. | 2011-11-24 |
20110287011 | DDR1-Binding Agents and Methods of Use Thereof - Disclosed are DDR1 binding agents and methods of using the agents for treating diseases such as cancer. The disclosure provides antibodies that specifically bind to an extracellular domain of DDR1 and modulate DDR1 activity. The disclosure further provides methods of using agents that modulate the activity of DDRI, such as antibodies that specifically bind DDR1, to reduce the tumorigenicity of tumors comprising cancer stem cells by reducing the frequency or number of cancer stem cells in the tumor. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer. | 2011-11-24 |
20110287012 | NUCLEIC ACID ENCODING CYTOKINE RECEPTOR ZCYTOR17 - Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 2011-11-24 |
20110287013 | NUCLEIC ACIDS CODING FOR ADHESION FACTOR OF GROUP B STREPTOCOCCUS, ADHESION FACTORS OF GROUP B STREPTOCOCCUS AND FURTHER USES THEREOF - The present invention is related to nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and uses thereof. More particularly, the present invention is related to a polypeptide being such adhesion factors and comprising an amino acid sequence, whereby the amino acid sequence is selected from the group comprising SEQ ID NO 11 to SEQ ID NO 20, and the use of such polypeptide for the manufacture of a vaccine. | 2011-11-24 |
20110287014 | ANTIBODIES DIRECTED AGAINST CALCIUM CHANNEL SUBUNIT ALPHA2/DELTA AND METHODS USING SAME - The present invention provides compositions comprising antibodies or polypeptides that specifically bind to an epitope in a von Willebrand Factor A (VWF-A) domain of a calcium channel subunit α2δ and induces synaptogenesis and methods of using the compositions for inducing synaptogenesis and neurite outgrowth. | 2011-11-24 |
20110287015 | MG53 COMPOSITIONS AND METHODS OF USE - Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins. | 2011-11-24 |
20110287016 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization. | 2011-11-24 |
20110287017 | ANTI-P-SELECTIN ANTIBODIES AND METHODS OF THEIR USE AND IDENTIFICATION - Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed. | 2011-11-24 |
20110287018 | Methods of Treating Interstitial Cystitis - The present invention relates to the use of IL-12 and/or IL-23 inhibitors for the treatment of a pain and/or a lower urinary tract symptom(s) (LUTS) associated with interstitial cystitis and/or painful bladder syndrome and/or bladder pain syndrome. | 2011-11-24 |
20110287019 | THERAPEUTIC TARGETING OF ESCORT PROTEINS - The invention provides for inhibition of viral disease by the provision to a mammalian host of antibodies directed against an escort protein like Tsg101. These proteins appear on the surface of a cell, and thus can be bound by circulating antibodies thereto. By binding escort proteins on the cell surface, budding of viral particles is inhibited. The virus infects the initial cells, but cannot escape that cell to infect the body en masse. | 2011-11-24 |
20110287020 | RECOMBINANT VECTORS - This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders. | 2011-11-24 |
20110287021 | NEOPLASM SPECIFIC ANTIBODIES AND USES THEREOF - The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms. | 2011-11-24 |
20110287022 | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS - The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognoses to patients having IFNα-induced disorders. | 2011-11-24 |
20110287023 | High Affinity Antibodies Against HMGB1 and Methods of Use Thereof - Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies. | 2011-11-24 |
20110287024 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS - The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization. | 2011-11-24 |
20110287025 | COMBINATION THERAPY AND METHOD FOR ASSESSING RESISTANCE TO TREATMENT - The present invention relates to a method for determining a subject's resistance to treatment with 2,2-dimethyl-N—((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N′-(2,2,3,3,3-pentafluoro-propyl)-malonamide by measuring the levels a biomarker or biomarkers present in a biological sample obtained from the subject, the biomarker being IL6 and/or IL8. The present invention also relates to a combination therapy for a patient suffering from a proliferative disorder comprising administering to the patient 2,2-Dimethyl-N—((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N′-(2,2,3,3,3-pentafluoro-propyl)-malonamide and an anti-IL6 and/or an anti-IL8 agent. | 2011-11-24 |
20110287026 | SIRT4 AND USES THEREOF - Provided herein are SIRT4 compositions and methods of use thereof. The invention provides functional information for use in the identification and design of compounds that modulate SIRT4 enzyme activity (e.g., inhibition of fatty acid oxidation, ADP ribosylation, and/or downregulation of glutamate dehydrogenase), and to the compounds identified by such methods and the research, diagnostic and therapeutic uses of such compounds. | 2011-11-24 |
20110287027 | Pain treatment - The present invention relates generally to a method for the treatment and prophylaxis of pain. In accordance with the present invention, it is proposed that antagonists of GM-CSF are effective in the treatment of pain. Antagonists of GM-CSF include, but are not limited to, antibodies which are specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models. | 2011-11-24 |
20110287028 | Methods of Treatment Using Human Anti-IL-23 Antibodies - A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 2011-11-24 |
20110287029 | INHIBITION OF THE BETA3 SUBUNIT OF L-TYPE CA2+ CHANNELS - The present invention provides reagents and methods for identifying inhibitors of the L-type Ca | 2011-11-24 |
20110287030 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AN INFLAMMATION - A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject. | 2011-11-24 |
20110287031 | Covalently reactive transition state analogs and methods of use thereof - Improved methods for the production, selection and inhibition of catalytic antibodies are disclosed. | 2011-11-24 |
20110287032 | NOVEL CTLA4-IG IMMUNOADHESINS - The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes. | 2011-11-24 |